Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An engineered CRISPR/Cas9 mouse line for simultaneous readout of lineage histories and gene expression profiles in single cells

ABSTRACT: An engineered CRISPR/Cas9 mouse line for simultaneous readout of lineage histories and gene expression profiles in single cells

PROVIDER: PRJNA612835 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11311900_1.fastq.gz	Fastqsanger.gz
	SRR11311900_2.fastq.gz	Fastqsanger.gz
	SRR11312000_1.fastq.gz	Fastqsanger.gz
	SRR11312000_2.fastq.gz	Fastqsanger.gz
	SRR11311901_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 470

Similar Datasets

An Engineered CRISPR-Cas9 Mouse Line for Simultaneous Readout of Lineage Histories and Gene Expression Profiles in Single Cells.

Project description:Tracing the lineage history of cells is key to answering diverse and fundamental questions in biology. Coupling of cell ancestry information with other molecular readouts represents an important goal in the field. Here, we describe the CRISPR array repair lineage tracing (CARLIN) mouse line and corresponding analysis tools that can be used to simultaneously interrogate the lineage and transcriptomic information of single cells in vivo. This model exploits CRISPR technology to generate up to 44,000 transcribed barcodes in an inducible fashion at any point during development or adulthood, is compatible with sequential barcoding, and is fully genetically defined. We have used CARLIN to identify intrinsic biases in the activity of fetal liver hematopoietic stem cell (HSC) clones and to uncover a previously unappreciated clonal bottleneck in the response of HSCs to injury. CARLIN also allows the unbiased identification of transcriptional signatures associated with HSC activity without cell sorting.

| S-EPMC7529102 | biostudies-literature

An engineered CRISPR/Cas9 mouse line for simultaneous readout of lineage histories and gene expression profiles in single cells

Project description:Tracing the lineage history of cells is key to answering diverse and fundamental questions in biology. Coupling of cell ancestry information with other molecular readouts represents an important goal in the field. Here, we describe the CARLIN (for CRISPR Array Repair LINeage tracing) mouse line and corresponding analysis tools that can be used to simultaneously interrogate the lineage and transcriptomic information of single cells in vivo. This model exploits CRISPR technology to generate up to 44,000 transcribed barcodes in an inducible fashion at any point during development or adulthood, is compatible with sequential barcoding, and is fully genetically defined. We have used CARLIN to identify intrinsic biases in the activity of fetal liver hematopoietic stem cell (HSC) clones and to uncover a previously unappreciated clonal bottleneck in the response of HSCs to injury. CARLIN also allows the unbiased identification of transcriptional signatures associated with HSC activity without cell sorting.

2020-03-17 | GSE146972 | GEO

Self-reporting transposons enable simultaneous readout of gene expression and transcription factor binding in single cells

Project description:Self-reporting transposons enable simultaneous readout of gene expression and transcription factor binding in single cells

| PRJNA624288 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Project description:Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

| PRJNA1010685 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CROPSeq_Data]

Project description:CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the chromosome, including in pre-clinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells, dramatically reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.

2023-11-18 | GSE241882 | GEO

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [Pilot_Data]

2023-11-18 | GSE241839 | GEO

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CART]

2023-11-18 | GSE241838 | GEO

Genetically engineered mouse models of sarcoma using CRISPR/Cas9

Project description:Generation and comparison of CRISPR/Cas9 and Cre-mediated genetically engineered mouse models of sarcoma

| PRJEB22279 | ENA

Simultaneous lineage tracing and cell type identification using CRISPR/Cas9 induced genetic scars

Project description:Simultaneous lineage tracing and cell type identification using CRISPR/Cas9 induced genetic scars

| PRJNA415636 | ENA

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells [CART]